Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

A state-licensed 503A compounding pharmacy is submitting a nomination to include BPC-157 as a bulk drug substance for compounding. They argue that BPC-157 is a chemically defined, water-soluble peptide with a favorable safety profile and significant preclinical evidence for various tissue repair and regenerative applications.

A state-licensed 503A compounding pharmacy is submitting a comment in support of the proposed nomination of MOTS-c (free base and acetate) as a bulk drug substance. The commenter provides extensive scientific literature and physicochemical data to argue that MOTS-c is a synthetic peptide with potential therapeutic applications in metabolic and age-related diseases that can be safely and reproducibly compounded.

A private individual opposes the proposed rule, arguing that it will limit the availability of beneficial compounded medications for patients with limited options. They express concern that the rule adds a bureaucratic barrier to healthcare and is medically irresponsible.

A veterinary student argues that the proposed restrictions on compounding drug combinations would negatively impact high-volume spay and neuter programs and limit access to veterinary care. They specifically request that the anesthetic combination of ketamine, tiletamine-zolazepam, and xylazine be exempt from the proposed framework due to its proven safety, homogeneity, and clinical necessity.

The commenter, likely a veterinary professional or clinic owner, argues that the proposed regulation imposes significant financial and operational burdens on veterinary practices and compounding pharmacies. They contend that the requirements lack a clear congressional mandate and will restrict clinical judgment and access to essential medications for patients.

The commenter supports the FDA's efforts to standardize the data required for substances on the 503A bulks list but argues for stricter evidentiary requirements, such as requiring at least one peer-reviewed source. They also recommend clarifying definitions for "historical use" versus "evidence of effectiveness," establishing minimum completeness thresholds for submissions, and issuing standardized public summaries of the decision rationales.

The commenter supports the FDA's new public docket for reviewing bulk drug substances for compounding, praising the requirement for scientific evidence and standardized submission formats. They argue that these measures are necessary for patient safety and regulatory consistency, while recommending further clarification on definitions for "historical use" and "justification for compounding."

The commenter, who appears to be a healthcare professional or student based on mentions of clinical rotations, supports the inclusion of various bulk drug substances for compounding. They specifically advocate for low-dose naltrexone and other substances like L-theanine and NAD to provide patients with alternative treatment options for autoimmune and inflammatory conditions.

A patient who uses Enclomiphene Citrate for hormone support argues that the medication is a safe and effective alternative to Clomid with fewer side effects. The commenter urges the FDA to include Enclomiphene on the 503A Bulk Substances List to ensure continued access to the drug for patients who rely on it for their quality of life and fertility.

Jenny Doss, a Family Nurse Practitioner, argues that the ingredients for the antihistamine Phenyltoloxamine should be released for compounding. She explains that this medication is a safer alternative to muscle relaxers for patients with sensitivities and that patients are currently forced to use old, potentially unsafe compounded supplies.